Amgen Inc. (NASDAQ: AMGN) reported second quarter 2019 adjusted EPS of $3.97 on revenue of $5.9 billion. Analysts had predicted the biotechnology firm to post earnings of $3.59 per share on revenue of $5.68 billion. Amgen stock advanced about 1% during the after-hours.
“With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders,” said CEO Robert Bradway.
Related: Advaxis’ revenue declines in Q2 as Amgen terminaties collaboration agreement
For full-year 2019, Amgen lifted its lower end of revenue outlook. The company now expects revenue to be in the range of $22.4 billion to $22.9 billion versus the prior estimaate of $22 billion to $22.9 billion.
FY19 GAAP earnings per share outlook revised to $12.10-$12.71 versus the prior outlook of $11.68-12.73 per share. The company also lifted its lower end of adjusted EPS outlook to a range of $13.75-14.30 from the earlier forecast of $13.25-14.30 per share.
While peers Pfizer (NYSE: PFE) reported its second quarter results yesterday, Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) reported their Q2 earnings results today morning. While Pfizer’s results failed to impress the market, Eli Lilly’s Q2 profit beat estimates. Merck’s second quarter results were far ahead of analysts’ expectations.
Amgen stock had given a negative return of 9% since the beginning of this year and dropped 8% in the trailing 12 months.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company